DocMorris AG

ROSE

CH0042615283

Drug Retailers

Real-time Estimate Cboe Europe Other stock markets 12:59:34 16/07/2024 pm IST			5-day change	1st Jan Change
48.08 ^CHF	+1.65%		-18.80%	-35.54%

12/07	DOCMORRIS : Hauck & Aufhauser reaffirms its Buy rating	ZD
12/07	DOCMORRIS : Deutsche Bank reiterates its Buy rating	ZD

ZUR ROSE GROUP : Baader Bank reiterates its Buy rating

January 21, 2021 at 10:29 pm IST

Baader Bank is positive on the stock with a Buy rating. The target price has been raised from CHF 320 to CHF 500.

Latest news about DocMorris AG

DOCMORRIS : Hauck & Aufhauser reaffirms its Buy rating	12/07	ZD
DOCMORRIS : Deutsche Bank reiterates its Buy rating	12/07	ZD
DOCMORRIS : Warburg Research maintains a Buy rating	11/07	ZD
DOCMORRIS : Sell rating from UBS	11/07	ZD
DocMorris' H1 Revenue Grows; FY24 Outlook Affirmed	11/07	MT
Redcare continues to recover - business with e-prescription picks up	04/07	DP
DOCMORRIS : Jefferies keeps its Buy rating	02/07	ZD
DOCMORRIS : Gets a Buy rating from Jefferies	19/06	ZD
DOCMORRIS : Jefferies gives a Buy rating	05/06	ZD
DOCMORRIS : Receives a Sell rating from UBS	04/06	ZD
Warburg: Several mid-caps attractive takeover targets - and Mercedes-Benz	27/05	DP
DOCMORRIS : Warburg Research reiterates its Buy rating	27/05	ZD
Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney...	23/05
DOCMORRIS : Gets a Buy rating from Baader Bank	22/05	ZD
UBS sends Redcare and DocMorris share prices plummeting	21/05	DP
DOCMORRIS : Gets a Sell rating from UBS	21/05	ZD
DOCMORRIS : Sell rating from UBS	16/05	ZD
DocMorris Names Successor to Outgoing CFO	08/05	MT
DocMorris Launches Tender Offer for Convertible Bonds Due 2025	06/05	MT
ROUNUP: E-prescription advertising squeezes profit margin of online pharmacy Redcare	25/04	DP
DOCMORRIS : Deutsche Bank remains its Buy rating	23/04	ZD
DOCMORRIS : Hauck & Aufhauser gives a Buy rating	19/04	ZD
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	18/04
DOCMORRIS : Gets a Buy rating from Warburg Research	18/04	ZD
DOCMORRIS : Receives a Buy rating from Berenberg	18/04	ZD

Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.

Sector

Drug Retailers

Calendar

20/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for DocMorris AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

47.3 CHF

Average target price

91.83 CHF

Spread / Average Target

+94.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
DOCMORRIS AG	-35.54%	681M
WALGREENS BOOTS ALLIANCE, INC.	-55.19%	10.1B
JD HEALTH INTERNATIONAL INC.	-46.42%	8.81B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-25.94%	6.65B
MATSUKIYOCOCOKARA & CO.	-4.16%	6.45B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+97.00%	5.35B
NAHDI MEDICAL COMPANY	-2.63%	4.63B
CLICKS GROUP LIMITED	+8.08%	4.6B
YIFENG PHARMACY CHAIN CO., LTD.	-32.12%	3.79B
REDCARE PHARMACY NV	+7.07%	3.13B

Other Drug Retailers

DocMorris AG

Equities

ROSE

CH0042615283

Drug Retailers

ZUR ROSE GROUP : Baader Bank reiterates its Buy rating

Latest news about DocMorris AG

Chart DocMorris AG

Company Profile

Income Statement Evolution

Ratings for DocMorris AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Drug Retailers